Form 4 for CRSP CRISPR Therapeutics AG

Accepted 2024-10-15 00:00:00 ET · period of report 2024-10-13 · accession 0000950170-24-114787 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-10-15	2024-10-13	CRSP	KASINGER JAMES R.	GC, Sec	M - OptEx	—	+2,113	63.7K	+3%	—
D	2024-10-15	2024-10-14	CRSP	KASINGER JAMES R.	GC, Sec	S - Sale+OE	$46.28	-1,089	62.6K	-2%	-$50.4K
D	2024-10-15	2024-10-13	CRSP	KASINGER JAMES R.	GC, Sec	M - OptEx	—	-2,113	4,227	-33%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2024-10-13	M	A	2,113	—	63,686	D	—	—	(F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F2) Includes 399 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
2	Common	Common Shares	2024-10-14	S	D	1,089	$46.28	62,597	D	—	—	(F3) Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
3	Derivative	Restricted Stock Units	2024-10-13	M	D	2,113	—	4,227	D	— · — to —	2,113 Common Shares	(F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F4) This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.